Integra LifeSciences Holdings Corp. (IART) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Integra LifeSciences is a global medical technology company operating in two reportable segments: Codman Specialty Surgical (neurosurgery, instruments, ENT) and Tissue Technologies (wound care, reconstruction). The company is currently navigating significant operational challenges related to FDA quality system issues at its Boston facility, a transition of manufacturing to a new Braintree facility, and the integration of the Acclarent acquisition.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $415.6M | $418.2M | $798.3M | $787.0M |
| Gross Margin % | 50.4% | 54.0% | 50.6% | 55.0% |
| Operating Income (Loss) | $(512.7M) | $(3.0M) | $(528.2M) | $0.9M |
| Net Loss | $(484.1M) | $(12.4M) | $(509.4M) | $(15.7M) |
| Diluted EPS | $(6.31) | $(0.16) | $(6.65) | $(0.20) |
| Cash & Equivalents | $217.9M | $246.4M (Dec '24) | N/A | |
| Working Capital | $213.0M | $159.6M (Dec '24) | N/A | |
| Total Debt (Carrying) | $1.84B | $1.80B (Dec '24) | N/A |
Material Changes vs. Prior Period
- Goodwill Impairment: The primary driver of the net loss was a non-cash goodwill impairment charge of $511.4 million recognized in Q2 2025. This was triggered by a decline in stock price and economic uncertainty related to tariffs. The impairment was allocated as follows:
- Codman Specialty Surgical: $388.1M
- Tissue Technologies: $123.3M
- Revenue Performance: Q2 2025 revenue declined slightly (1%) year-over-year due to quality and operational issues, partially offset by growth in the Codman Specialty Surgical segment (driven by CSF Management products). YTD revenue grew 1.4% primarily due to the inclusion of Acclarent sales.
- Gross Margin Compression: Gross margin percentage decreased from 54.0% in Q2 2024 to 50.4% in Q2 2025. This was driven by quality/operational issues, higher manufacturing costs, and the impact of tariffs.
- Cash Flow: Operating cash flow turned negative at $(2.3M) for the six months ended June 30, 2025, compared to positive $56.2M in the prior year period, largely due to working capital increases (inventory and prepaid expenses) and lower operating income.
Guidance, Outlook, Risks, and Unusual Items
- Manufacturing Transition: The company is transitioning production of key products (SurgiMend, PriMatrix, Durepair) from the Boston facility to a new facility in Braintree, Massachusetts. The Braintree facility is expected to be operational in 2026. PMA approvals for SurgiMend and DuraSorb are also targeted for 2026.
- Regulatory Risks: The company received an FDA Warning Letter in December 2024 regarding quality system issues at three facilities. While not restricting current manufacturing, PMAs for Class III devices will not be approved until violations are corrected. Several derivative lawsuits regarding these issues were filed in 2025; one was dismissed with prejudice, while others remain active.
- Tariff Impact: New U.S. tariffs and reciprocal measures from China are expected to increase costs of goods sold. The company paid approximately $5.4M in tariffs YTD 2025. Management has amended its Senior Credit Facility covenants to provide relief through Q4 2026 to maintain compliance amidst these headwinds.
- Debt Covenants: As of June 30, 2025, the Consolidated Total Leverage Ratio was 4.53x, within the amended covenant limit of 5.00x. The company has sufficient capacity under its revolving credit facility to repay the $575M Convertible Senior Notes maturing in August 2025.
- Special Charges: Excluding goodwill impairment, special charges totaled $35.2M for Q2 2025, including costs for the Boston recall, Braintree transition, and EU MDR compliance.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the discount rates (12.0% - 13.5%) and terminal growth rates (2.5%) used in the quantitative impairment testing.
- Braintree Facility Timeline: Monitor progress on the construction and FDA approval of the Braintree facility, as delays could further impact revenue and PMA approvals.
- FDA Resolution: Track the status of responses to the December 2024 Warning Letter and Form 483s to ensure no further regulatory actions are taken.
- Tariff Exposure: Assess the extent to which tariff costs can be passed on to customers versus absorbed, given the 50% of global revenue from U.S. manufactured products.
- Liquidity Position: Confirm the ability to service the $575M Convertible Notes due in August 2025 and maintain covenant compliance under the amended credit facility.